U.S. Markets open in 4 hrs 20 mins

US Nuclear Corp. (UCLE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1700-0.0590 (-25.76%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2290
Open0.1870
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1700 - 0.2290
52 Week Range0.1031 - 1.4100
Volume96,881
Avg. Volume48,964
Market Cap3.969M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-0.1490
Earnings DateSep 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • US Nuclear and Grapheton Brain Implants to Help Immobilized Patients
    GlobeNewswire

    US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

    LOS ANGELES, CA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – US Nuclear (OTC: UCLE) and Grapheton’s implantable bioelectronic sensors can be used to help treat millions of people world-wide suffering from mobility problems. Neuroscientists stress there is a large unmet demand to develop implantable sensors and the artificial intelligence required to translate the brain signals into specific commands or actions. As many as 500,000 people worldwide suffer spinal cord injuries every year and approximately 1.7% of the U.S. population or 5.4 million people suffer from some form of paralysis.  Furthermore, COVID-19 has caused an increase in the number of strokes, especially among younger individuals.  Fortunately, Grapheton has already developed various types of implantable brain sensors, including ECoG (electrocorticography- monitoring the electrical activity of the brain), spinal stimulation probes, and brain chemical sensors, all of which are already in use at various research centers. Unlike most other developers, Grapheton’s probes are biocompatible, thus avoiding inflammation.  Grapheton already has several other patented advantages that solve some of the issues with the current technology, including:  1. Created new multifunctional probes for simultaneous electrical and chemical detection over large brain area neural circuits. 2. New graphene-polymer carbon-based electrode that doesn’t corrode and can last as long as 40 years or more, thereby eliminating or greatly reducing the surgery required for maintenance.  Current probes from other providers only last between 1-5 years before requiring surgery again.   3. Grapheton fabricates their own implantable integrated circuits. In the future, these may supplement or augment brain function. 4. New self-charging battery that uses the brain’s own salty liquid environment as the power source, negating the need for additional cranial surgeries for battery replacement and maintenance.   5. New two-way electrical and chemical communication with brain neurons, which allows more effective, tailored, and on-demand electrical stimulation, and eliminates most of the current side-effects thus allowing treatment of a wider variety of patients.  Recent research in neurotechnology is aimed at recording as many brain cells or regions as possible in order to provide more precise data on the signals that govern speech, walking, and grasping.  These signals are transmitted to a control unit, which are processed and translated into instructions, and can then be sent into a robotic device or back into the body’s nervous system to produce movement, vision, or even the sensation of touch. The technology is still in the early stages, but will continuously improve with further research and clinical trials that are already underway.  US Nuclear and Grapheton’s brain-machine interface technology has tremendous potential for helping immobilized patients gain mobility once again and perform actions that would have never been possible without this revolutionary product.  Safe Harbor Act This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.comCONTACT:US Nuclear Corp. (OTC: UCLE) Robert I. Goldstein, President, CEO, and Chairman  Rachel Boulds, Chief Financial Officer (818) 883 7043 Email: info@usnuclearcorp.com

  • GlobeNewswire

    US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

    LOS ANGELES, CA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.     Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics are becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future.  In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.   Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.Bioelectronics have several key advantages over traditional treatment methods. The primary advantage is that bioelectronics can be used to treat conditions that current drugs or procedures are unable to treat (i.e., spinal-cord injuries, addiction, depression, Parkinson’s, stroke, multiple sclerosis, regaining vision, and more). A second major advantage is the ability to deliver precise treatment.  For example, a bioelectronic device is used to treat paralysis from a stroke or brain injury by specifically bridging the damaged site and restoring motor transmission, whereas the pharmaceutical approach of prescribing drugs is diffuse, lacking the necessary precision targeting to be effective. Additionally, almost all drugs have the potential for undesired side effects which can build up to severe problems over the course of treatment. Many drugs are given for continuous use of pills or injections, over months or years, whereas bioelectronic interventions are designed to repair a problem permanently while allowing for periodic non-invasive adjustments made by the user, doctor, or automatically. Bioelectronic devices can also provide precise, localized regulation of misbehaving glands and organs. Biomedicine is translating new discoveries in science and biological systems into needed medical care and treatment. It utilizes under-recognized electrical and neuro systems and pathways that take advantage of the body’s innate functions. Robert Goldstein, CEO of US Nuclear, will bring decades of manufacturing, marketing, and leadership experience to help to accelerate Grapheton’s growth into a world leader in bioelectronics technology. Safe Harbor ActThis press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.comCONTACT:US Nuclear Corp. (OTC: UCLE) Robert I. Goldstein, President, CEO, and Chairman  Rachel Boulds, Chief Financial Officer (818) 883 7043 Email: info@usnuclearcorp.com

  • GlobeNewswire

    US Nuclear: Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

    Los Angeles, CA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- As the construction of the huge ITER tokamak grows towards completion, the tritium monitoring market is soaring.  As the world leader in quality tritium monitoring instrumentation, US Nuclear’s (OTC: UCLE) Overhoff division is poised to capture a large portion of this business.  The ITER fusion project seeks to develop a major new source of electric power to help supply the world’s fast-growing appetite for dependable, 24/7 electric power. Fusion is fueled by tritium and deuterium, which are both isotopes of hydrogen.  Tritium is in short supply and ITER will fully deplete the global inventory. ITER is a $20+ billion international scientific and engineering project jointly funded by the European Union, China, India, Japan, Russia, South Korea, and the United States.TRITIUM USAGE As a fuel source, tritium is required for ITER and for all other fusion energy projects, but it has many other uses as well.  Tritium is used as a radioactive tracer in biomedical and academic research, for producing urgently needed medical scanning isotopes Mo-99 and Tc-99m, designing and testing new pharmaceutical drugs, and providing vital lighting for remote airfields, exit signs, and gun sights.  Of course, tritium is also essential for maintaining a deteriorating US nuclear weapons stockpile.    TRITIUM SUPPLY Deuterium can be extracted from seawater relatively easily, but tritium is only produced significantly in nuclear reactors.  The current global inventory is only about 20 kilos!  Tritium is in short supply and ITER hopes to draw from the global inventory.  Supplies may be insufficient until eventually the fusion reaction is established and hopefully the tritium can be ‘bred’ within ITER. The Tennessee Valley Authority, Savannah River Site, and others are all gearing up for tritium production and recapitalization, which means that much more tritium monitoring instrumentation is needed right now and going forward.  US Nuclear’s Overhoff division is booming with business, with a large backlog of orders and many more in the pipeline.  Overhoff customers include: DOE national labs, nuclear power plants, pharmaceutical companies, and US/NATO air force and nuclear navies. Safe Harbor Act This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.comCONTACT:US Nuclear Corp. (OTC: UCLE)Robert I. Goldstein, President, CEO, and Chairman Rachel Boulds, Chief Financial Officer(818) 883 7043Email: info@usnuclearcorp.com